Target intelligence / Profile preview

Bacterial autolysin (ATL)

Target
ATL
Molecular classification
Enzyme, Hydrolase, Peptidoglycan hydrolase
01

Overview

Bacterial autolysins are endogenous peptidoglycan hydrolases that play a critical role in cell wall maintenance, including cell wall turnover, cell division, and the separation of daughter cells. These enzymes cleave the covalent bonds within the peptidoglycan matrix, allowing the insertion of new cell wall material during growth. Beyond structural maintenance, autolysins act as virulence factors by facilitating biofilm formation, bacterial adhesion to host tissues, and the release of extracellular DNA. Because of their essential role in bacterial viability and pathogenesis, autolysins are highly attractive therapeutic targets. Traditional bactericidal antibiotics, such as penicillins and vancomycin, exert their effects in part by triggering uncontrolled autolysin activity, leading to bacterial self-destruction. Newer therapeutic strategies focus on directly inhibiting autolysins using novel glycopeptides like complestatin and corbomycin, which bind peptidoglycan to block autolysin access, or utilizing recombinant autolysins as direct enzybiotics to lyse drug-resistant strains.

Other names
Bacterial autolysinsPeptidoglycan hydrolaseMurein hydrolaseAutolysin AAtlALytALytCLytDLytFLytNCell wall hydrolase
02

Mechanism of action

Antibiotics like penicillins and vancomycin induce bacterial autolysis by activating or derepressing autolysins, leading to cell wall degradation and cell death. Conversely, type V glycopeptide antibiotics like complestatin and corbomycin bind directly to peptidoglycan, physically blocking autolysins from accessing and remodeling the cell wall, which traps the bacteria and prevents division. Recombinant autolysins (enzybiotics) can also be administered exogenously to directly digest the bacterial cell wall.

03

Biological functions

Cell wall turnoverCell divisionDaughter cell separationBiofilm formationBacterial adhesionAutolysisPeptidoglycan recycling
04

Disease associations

InfectionSepsisPneumoniaEndocarditisBiofilm-associated infection
05

Safety considerations

Release of highly immunogenic and pro-inflammatory bacterial components (e.g., pneumolysin, peptidoglycan fragments, muramyl dipeptide) during rapid lysis, which can exacerbate host inflammatory responses and sepsisPotential for resistance development through cell wall modifications or signaling mutations (e.g., VraSR two-component system)Suboptimal targeting of exogenous autolysins to the bacterial cell wall due to localized native binding domains
06

Interacting drugs

Complestatin

4 more in the full profile.

07

Biomarkers

LytA gene expressionAtlA protein levelsPeptidoglycan fragmentsMuramyl dipeptide (MDP) levels

Beyond the preview

Go deeper on Bacterial autolysin (ATL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial autolysin (ATL).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call